Travoprost in the Treatment of Ocular Hypertension
Purpose: To compare the daily versus the alternate day use of travoprost 0.004% in lowering the intraocular pressure (IOP) in patients with ocular hypertension.
Methods: Fourteen patients with ocular hypertension in both eyes have been randomly assigned to receive travoprost 0.004% once a day in 1 eye and once every other day in the other eye. The main outcome measure was change in the mean of the IOPs measured at 9:00 AM, and 4:00 PM between baseline (before treatment) and measurement of IOPs at 1, 2, 4, 8, and 12 weeks after treatment.
Results: After 3 months of treatment, daily use of travoprost 0.004% significantly reduced IOP (mean±standard error of mean) by 6.1±0.5 mmHg (P<0.001) and alternate day use by 5.9±0.3 mmHg (P< 0.001) adjusted from an overall baseline of 24.3±0.5 mm Hg. The difference in the IOP-lowering effect was not statistically significant (P<0.05).
Conclusions: Alternate day use of travoprost 0.004% was as safe and effective as its daily use in lowering the IOP in patients with ocular hypertension.
Prostaglandin analogues have been widely used effectively as a first line for the treatment of ocular hypertension and primary open angle glaucoma. Reduction of intraocular pressure (IOP) from travoprost and other prostaglandin analogues is thought to result largely through stimulation of prostaglandin receptors. Stimulation of prostaglandin receptors cause remodelling of the extracellular matrix of the ciliary body, which leads to increase in the space between ciliary muscle fibers, thus increasing outflow through uveoscleral outflow. The majority of the randomized controlled trials have found travoprost to be equally efficacious in comparison with latanoprost and bimatoprost in eyes with ocular hypertension and primary open angle glaucoma. Recent trials have suggested that travoprost has a robust effect in lowering of IOP with little diurnal fluctuation, which can last beyond the standard dosing interval of 24 hours. Other pilot trials suggested that the travoprost effect can continue up to 84 hours after the final dose. In this study, we explored the possibility of using travoprost every 48 hours and compared its effect with its standard 24 hours dosage.
Abstract and Introduction
Abstract
Purpose: To compare the daily versus the alternate day use of travoprost 0.004% in lowering the intraocular pressure (IOP) in patients with ocular hypertension.
Methods: Fourteen patients with ocular hypertension in both eyes have been randomly assigned to receive travoprost 0.004% once a day in 1 eye and once every other day in the other eye. The main outcome measure was change in the mean of the IOPs measured at 9:00 AM, and 4:00 PM between baseline (before treatment) and measurement of IOPs at 1, 2, 4, 8, and 12 weeks after treatment.
Results: After 3 months of treatment, daily use of travoprost 0.004% significantly reduced IOP (mean±standard error of mean) by 6.1±0.5 mmHg (P<0.001) and alternate day use by 5.9±0.3 mmHg (P< 0.001) adjusted from an overall baseline of 24.3±0.5 mm Hg. The difference in the IOP-lowering effect was not statistically significant (P<0.05).
Conclusions: Alternate day use of travoprost 0.004% was as safe and effective as its daily use in lowering the IOP in patients with ocular hypertension.
Introduction
Prostaglandin analogues have been widely used effectively as a first line for the treatment of ocular hypertension and primary open angle glaucoma. Reduction of intraocular pressure (IOP) from travoprost and other prostaglandin analogues is thought to result largely through stimulation of prostaglandin receptors. Stimulation of prostaglandin receptors cause remodelling of the extracellular matrix of the ciliary body, which leads to increase in the space between ciliary muscle fibers, thus increasing outflow through uveoscleral outflow. The majority of the randomized controlled trials have found travoprost to be equally efficacious in comparison with latanoprost and bimatoprost in eyes with ocular hypertension and primary open angle glaucoma. Recent trials have suggested that travoprost has a robust effect in lowering of IOP with little diurnal fluctuation, which can last beyond the standard dosing interval of 24 hours. Other pilot trials suggested that the travoprost effect can continue up to 84 hours after the final dose. In this study, we explored the possibility of using travoprost every 48 hours and compared its effect with its standard 24 hours dosage.
SHARE
